Psyence Biomedical (PBM)
Market Price (3/30/2026): $2.55 | Market Cap: $0.6 MilSector: Health Care | Industry: Biotechnology
Psyence Biomedical (PBM)
Market Price (3/30/2026): $2.55Market Cap: $0.6 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -1178% | Weak multi-year price returns2Y Excs Rtn is -122%, 3Y Excs Rtn is -162% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Megatrend and thematic driversMegatrends include Mental Health Innovation. Themes include Psychedelic-Assisted Therapy Development, Neuropsychiatric Drug Discovery, and Palliative Care Solutions. | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -3.1 Mil | |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -196% | ||
| High stock price volatilityVol 12M is 538% | ||
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 31% | ||
| Key risksPBM key risks include [1] potential delays in its pivotal Phase IIb clinical trials and [2] maintaining Nasdaq listing compliance given its substantial quarterly losses and lack of revenue. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -1178% |
| Megatrend and thematic driversMegatrends include Mental Health Innovation. Themes include Psychedelic-Assisted Therapy Development, Neuropsychiatric Drug Discovery, and Palliative Care Solutions. |
| Weak multi-year price returns2Y Excs Rtn is -122%, 3Y Excs Rtn is -162% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -3.1 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -196% |
| High stock price volatilityVol 12M is 538% |
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 31% |
| Key risksPBM key risks include [1] potential delays in its pivotal Phase IIb clinical trials and [2] maintaining Nasdaq listing compliance given its substantial quarterly losses and lack of revenue. |
Qualitative Assessment
AI Analysis | Feedback
Psyence Biomedical (PBM) stock has lost about 95% since 11/30/2025 because of the following key factors:
1. Significant Share Dilution from a Major Share-for-Share Exchange.
On February 25, 2026, Psyence Biomedical completed a share-for-share exchange in which it issued 1,146,159 common shares. This transaction stemmed from Psyence Labs Ltd. exercising an irrevocable put option, valued at US$5,000,000, to require Psyence Biomedical to subscribe for its ordinary shares. The issuance of these new common shares significantly altered the company's capital structure, with Psyence Labs becoming the dominant shareholder, holding approximately 49.98% of the equity, which likely diluted the ownership and value for existing shareholders.
2. Multiple Reverse Stock Splits Indicating Underlying Financial Instability.
Psyence Biomedical implemented a second reverse stock split (share consolidation) at a ratio of 1-for-6.25, effective February 2, 2026, following board approval on December 4, 2025. This came after an earlier 1-for-7.97 consolidation in May 2025. These actions reduced the company's outstanding common shares from 6,388,604 to approximately 1,022,177. Repeated reverse stock splits are frequently used by companies to artificially inflate their share price to meet stock exchange listing requirements, signaling ongoing financial challenges and eroding investor confidence.
Show more
1. Significant Share Dilution from a Major Share-for-Share Exchange.
On February 25, 2026, Psyence Biomedical completed a share-for-share exchange in which it issued 1,146,159 common shares. This transaction stemmed from Psyence Labs Ltd. exercising an irrevocable put option, valued at US$5,000,000, to require Psyence Biomedical to subscribe for its ordinary shares. The issuance of these new common shares significantly altered the company's capital structure, with Psyence Labs becoming the dominant shareholder, holding approximately 49.98% of the equity, which likely diluted the ownership and value for existing shareholders.
2. Multiple Reverse Stock Splits Indicating Underlying Financial Instability.
Psyence Biomedical implemented a second reverse stock split (share consolidation) at a ratio of 1-for-6.25, effective February 2, 2026, following board approval on December 4, 2025. This came after an earlier 1-for-7.97 consolidation in May 2025. These actions reduced the company's outstanding common shares from 6,388,604 to approximately 1,022,177. Repeated reverse stock splits are frequently used by companies to artificially inflate their share price to meet stock exchange listing requirements, signaling ongoing financial challenges and eroding investor confidence.
Show more
Stock Movement Drivers
Fundamental Drivers
The -95.7% change in PBM stock from 11/30/2025 to 3/29/2026 was primarily driven by a 0.0% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 11302025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 59.96 | 2.56 | -95.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 0 | 0 | 0.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
11/30/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| PBM | -95.7% | |
| Market (SPY) | -5.3% | 4.4% |
| Sector (XLV) | -8.7% | 4.4% |
Fundamental Drivers
The -97.7% change in PBM stock from 8/31/2025 to 3/29/2026 was primarily driven by a -97.7% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 8312025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 109.77 | 2.56 | -97.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | � | 0 | 0.0% |
| P/S Multiple | � | ∞ | 0.0% |
| Shares Outstanding (Mil) | 0 | 0 | -97.7% |
| Cumulative Contribution | 0.0% |
Market Drivers
8/31/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| PBM | -97.7% | |
| Market (SPY) | 0.6% | 5.6% |
| Sector (XLV) | 5.2% | 2.7% |
Fundamental Drivers
The -99.3% change in PBM stock from 2/28/2025 to 3/29/2026 was primarily driven by a -97.7% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 2282025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 386.05 | 2.56 | -99.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | � | 0 | 0.0% |
| P/S Multiple | � | ∞ | 0.0% |
| Shares Outstanding (Mil) | 0 | 0 | -97.7% |
| Cumulative Contribution | 0.0% |
Market Drivers
2/28/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| PBM | -99.3% | |
| Market (SPY) | 9.8% | 8.5% |
| Sector (XLV) | -2.1% | 7.0% |
Fundamental Drivers
nullnull
Market Drivers
2/28/2023 to 3/29/2026| Return | Correlation | |
|---|---|---|
| PBM | ||
| Market (SPY) | 69.4% | 7.3% |
| Sector (XLV) | 18.4% | 5.6% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| PBM Return | - | - | - | -99% | -96% | -91% | -100% |
| Peers Return | -70% | -86% | -49% | 1173% | 11% | -27% | -78% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -5% | 72% |
Monthly Win Rates [3] | |||||||
| PBM Win Rate | - | - | - | 17% | 25% | 67% | |
| Peers Win Rate | 12% | 25% | 29% | 38% | 46% | 17% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| PBM Max Drawdown | - | - | - | -99% | -96% | -98% | |
| Peers Max Drawdown | -70% | -87% | -52% | -55% | -65% | -30% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -5% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: DRUG, ENVB.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/27/2026 (YTD)
How Low Can It Go
PBM has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -16.1% | -25.4% |
| % Gain to Breakeven | 19.1% | 34.1% |
| Time to Breakeven | 599 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -28.8% | -33.9% |
| % Gain to Breakeven | 40.4% | 51.3% |
| Time to Breakeven | 116 days | 148 days |
| 2018 Correction | ||
| % Loss | -15.8% | -19.8% |
| % Gain to Breakeven | 18.8% | 24.7% |
| Time to Breakeven | 326 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -40.6% | -56.8% |
| % Gain to Breakeven | 68.3% | 131.3% |
| Time to Breakeven | 1,100 days | 1,480 days |
Compare to DRUG, ENVB
In The Past
SPDR Select Sector Fund's stock fell -16.1% during the 2022 Inflation Shock from a high on 4/8/2022. A -16.1% loss requires a 19.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Psyence Biomedical (PBM)
AI Analysis | Feedback
nullAI Analysis | Feedback
nullAI Analysis | Feedback
nullAI Analysis | Feedback
nullAI Analysis | Feedback
```htmlJody Aufrichtig Chief Executive Officer
Jody Aufrichtig is an award-winning entrepreneur, business builder, impact investor, and philanthropist. A Chartered Accountant by training, he has built significant shareholder value in 19 businesses across various sectors including cannabis, private equity, travel and tourism, and sport and leisure. He previously headed Canopy Growth's African operations and has 25 years of private equity experience. He was awarded Entrepreneur of the Year in 2023.
Warwick Corden-Lloyd Chief Financial Officer
Warwick Corden-Lloyd is a Chartered Accountant and Certified Project Manager with over 17 years of experience in the United Kingdom, the USA, and South Africa. His experience spans advising boards of publicly traded companies and designing strategies for start-ups. He previously served as VP Operations and Finance for Canopy Growth Africa and, before that, was the Head of Financial Accounting for Capitec Bank. He is experienced in IPOs, capital raises, M&A, regulatory affairs, compliance, and corporate governance.
Dr. Neil Maresky Global Head Clinical Development
Dr. Neil Maresky, a trained MD in Emergency Medicine and Family Practice, is the Chief Executive Officer of Psyence Group and previously served as CEO of Psyence Biomedical Ltd. He has over 17 years of experience in research-based pharmaceuticals, having held positions with Wyeth, Bayer, and Novartis, and was the Vice President Scientific Affairs at AstraZeneca, Canada Inc. Dr. Maresky also served as Director of Drug Safety and Pharmaco-epidemiology. He has over 25 years of experience leading Research and Development for large pharmaceutical companies.
```AI Analysis | Feedback
Key Risks to Psyence Biomedical (PBM)
- Clinical Trial Failure and Inability to Obtain Regulatory Approvals: As a biopharmaceutical company specializing in psychedelic-based therapeutics, Psyence Biomedical's core business relies heavily on the successful outcome of its clinical trials and subsequent regulatory approvals. The company's products are currently in the preclinical or clinical development phases, including an ongoing Phase IIb clinical trial for psilocybin. There is a high rate of failure for product candidates in clinical trials. Delays in, or the failure to obtain, necessary regulatory approvals (such as from the FDA or similar authorities) for its proposed psilocybin-based medicines would severely impede the commercial success of its products and materially adversely affect the company's business, prospects, financial condition, and results of operations. Even if regulatory approvals are initially secured, there is a risk that a proposed drug could later be found ineffective or unsafe, potentially leading to its withdrawal from the market. Furthermore, the efficacy and safety of psychedelic compounds for medical use have not been definitively confirmed by extensive authorized clinical research.
- Lack of Revenue and Sustained Losses: Psyence Biomedical has a limited operating history and has not generated any revenue to date, incurring losses since its inception. The company expects to continue incurring significant losses for the foreseeable future and there is no assurance that it will ever be profitable or successfully commercialize marketable products. While the company may exhibit strong liquidity, its reliance on debt and the absence of profitable operations pose significant financial challenges, making it difficult to predict its future performance.
- Evolving and Uncertain Regulatory Landscape and Market Acceptance: Psyence Biomedical operates within the nascent and highly regulated psychedelic therapy industry. There is no guarantee that this industry and market will continue to exist and grow as currently estimated or anticipated, or that it will evolve in a manner consistent with management's expectations. Any event or circumstance that negatively affects the psychedelic therapy industry and market, including changes in laws, regulations, or public perception, could have a material adverse effect on Psyence's business. The company must also make significant investments to build brand awareness, operational capacity, and ensure compliance with complex and evolving regulations in this specialized market.
AI Analysis | Feedback
nullAI Analysis | Feedback
Psyence Biomedical (PBM) focuses on developing nature-derived psilocybin-based and ibogaine-based psychedelic medicines for mental health disorders, particularly within the context of palliative care, targeting conditions such as anxiety, depression, and adjustment disorder. The addressable markets for their main products and services fall under the broader psychedelic drugs market and the more specific psilocybin-assisted therapy market.
- Global Psychedelic Drugs Market: This market was valued at approximately USD 4.08 billion in 2025 and is estimated to grow from USD 4.63 billion in 2026 to reach USD 8.75 billion by 2031, demonstrating a Compound Annual Growth Rate (CAGR) of 13.55% during this forecast period. North America leads this market, holding a 51.60% share in 2025. Another projection indicates the global psychedelic drugs market size was USD 1.82 billion in 2025 and is projected to grow from USD 2.04 billion in 2026 to USD 5.16 billion by 2034, at a CAGR of 12.27%. Psilocybin alone holds approximately 34% of the psychedelic drugs market share. The market is estimated to grow from USD 2.77 billion in 2024 to USD 3.19 billion in 2025 and is expected to reach USD 12.89 billion by 2035, growing at a CAGR of 15%.
- Global Psilocybin Assisted Therapy Market: This market was valued at USD 3.1 billion in 2025 and is projected to reach USD 11.8 billion by the end of 2035, with a CAGR of 15.8% during the period of 2026-2035. In 2026, the market size for psilocybin-assisted therapy is estimated at USD 3.6 billion. North America is anticipated to command a 55.3% share of this market by 2035.
AI Analysis | Feedback
```htmlExpected Drivers of Future Revenue Growth for Psyence Biomedical (PBM)
Psyence Biomedical (PBM) is a life science biotechnology company focused on developing botanical psilocybin-based psychedelic medicines, particularly for mental health disorders within palliative care, and is also advancing ibogaine-based therapies. As the company currently reports no meaningful revenue, its future revenue growth over the next 2-3 years will primarily be driven by the successful progression and commercialization of its pipeline products and strategic initiatives.
- Successful Clinical Trials and Commercialization of PEX010: A primary driver of future revenue growth will be the successful completion of the Phase IIb clinical study for its lead product candidate, PEX010. PEX010 is a capsule containing naturally sourced psilocybin aimed at treating adjustment disorder, anxiety, and depression in patients with incurable cancer in a palliative care context. Positive trial results and subsequent regulatory approvals will be crucial for market entry and revenue generation.
- Expansion of Product Pipeline with Ibogaine Therapies: Psyence Biomedical is actively developing ibogaine-based psychedelic medicines. The company has secured GMP-compliant supplies of pharmaceutical-grade ibogaine through its partnership with PsyLabs. Advancing these ibogaine therapies through clinical development and towards commercialization represents a significant additional revenue stream beyond psilocybin.
- Strategic Partnerships and Collaborations: Ongoing and new strategic partnerships, such as those with iNGENu Pty Ltd for clinical trials and PsyLabs for manufacturing and supply, are expected to facilitate product development and market access. These collaborations could lead to licensing agreements, joint ventures, or expanded distribution channels, contributing to revenue growth.
- Geographic Market Expansion: While current clinical trials for PEX010 are focused in Australia, successful outcomes could enable the company to expand into other international markets. Entering new geographies would broaden the potential patient base and market share for its psychedelic-based therapeutics.
- Advancements in AI-driven Drug Development: Psyence Biomedical has expressed interest in AI-driven drug development initiatives and neuroscience research. Should these initiatives lead to the discovery of new product candidates or significantly accelerate the development timeline of existing ones, it could provide a substantial long-term driver for revenue growth by expanding the company's therapeutic offerings.
AI Analysis | Feedback
Share Repurchases
- On January 12, 2026, Psyence Biomedical Ltd. announced a share repurchase program, with no specified expiration date, aimed at protecting and enhancing shareholder value.
Share Issuance
- The company completed a business combination agreement with Newcourt Acquisition Corp. (a SPAC) on January 25, 2024, leading to PBM's listing on NASDAQ.
- Psyence Biomedical has conducted multiple reverse stock splits to maintain its Nasdaq listing, including a 1-for-75 consolidation on November 26, 2024, a 1-for-7.97 consolidation on May 5, 2025, and a 1-for-6.25 reverse stock split effective February 2, 2026, reducing outstanding shares from 6,388,604 to approximately 1,022,177.
- On February 25, 2026, the company issued 1,146,159 common shares in a share-for-share exchange with Psyence Labs Ltd. for an equivalent value of US$5,000,000, significantly diluting existing shareholders and making Psyence Labs the dominant shareholder.
Inbound Investments
- Psyence has financed its operations primarily through the sale of equity securities and convertible debt financings since its inception.
- The share-for-share exchange completed on February 25, 2026, involved Psyence Biomedical issuing shares in return for Psyence Labs Ltd.'s ordinary shares valued at US$5,000,000, securing strategic supply and strengthening the commercialization pathway.
Outbound Investments
- Psyence BioMed made a "multi-million-dollar follow-on investment in PsyLabs" to secure GMP nature-derived psilocybin and ibogaine supply for its clinical programs.
- The company holds a strategic equity stake in PsyLabs and has secured a right of first refusal to acquire exclusive rights to a dedicated supply of Ibogaine.
Capital Expenditures
- Capital expenditures were approximately -$3,677 for the 12 months prior to March 11, 2026.
- Annual cash flow statements show capital expenditures of -$0.01 million for the fiscal year ended March 31, 2025, and -$0.006 million for the fiscal year ended March 31, 2024.
- The primary focus of the company's capital allocation, while not necessarily categorized as capital expenditures, is on developing nature-derived psilocybin-based psychedelic medicine and advancing its Phase IIb clinical trial in Australia.
Trade Ideas
Select ideas related to PBM.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | QDEL | QuidelOrtho | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | CHE | Chemed | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | LLY | Eli Lilly | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02202026 | HAE | Haemonetics | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.5% | 3.5% | 0.0% |
| 02132026 | IQV | IQVIA | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 7.1% | 7.1% | -3.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 2.56 |
| Mkt Cap | 0.0 |
| Rev LTM | 0 |
| Op Inc LTM | -9 |
| FCF LTM | -11 |
| FCF 3Y Avg | -8 |
| CFO LTM | -11 |
| CFO 3Y Avg | -8 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | - |
| Rev Chg 3Y Avg | - |
| Rev Chg Q | - |
| QoQ Delta Rev Chg LTM | - |
| Op Mgn LTM | - |
| Op Mgn 3Y Avg | - |
| QoQ Delta Op Mgn LTM | - |
| CFO/Rev LTM | - |
| CFO/Rev 3Y Avg | - |
| FCF/Rev LTM | - |
| FCF/Rev 3Y Avg | - |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.0 |
| P/S | - |
| P/EBIT | -0.5 |
| P/E | -0.5 |
| P/CFO | -21.0 |
| Total Yield | -192.2% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -168.4% |
| D/E | 0.0 |
| Net D/E | -2.4 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -16.4% |
| 3M Rtn | -54.3% |
| 6M Rtn | -74.1% |
| 12M Rtn | -89.3% |
| 3Y Rtn | -99.4% |
| 1M Excs Rtn | -10.2% |
| 3M Excs Rtn | -51.4% |
| 6M Excs Rtn | -70.7% |
| 12M Excs Rtn | -101.8% |
| 3Y Excs Rtn | -161.2% |
Price Behavior
Price Behavior
| Market Price | $2.56 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 01/26/2024 | |
| Distance from 52W High | -99.4% | |
| 50 Days | 200 Days | |
| DMA Price | $4.10 | $100.37 |
| DMA Trend | down | down |
| Distance from DMA | -37.6% | -97.4% |
| 3M | 1YR | |
| Volatility | 1,050.8% | 542.5% |
| Downside Capture | 6.43 | 4.97 |
| Upside Capture | -225.72 | 141.44 |
| Correlation (SPY) | 5.9% | 8.2% |
PBM Betas & Captures as of 2/28/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 26.85 | 8.09 | 5.56 | 4.13 | 2.46 | 1.41 |
| Up Beta | -29.12 | -15.39 | -10.52 | -5.65 | 0.24 | -0.50 |
| Down Beta | 4.59 | 4.08 | 3.26 | 3.26 | 2.33 | 0.80 |
| Up Capture | 9387% | -737% | -543% | -187% | -24% | -7% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 8 | 13 | 21 | 50 | 100 | 187 |
| Down Capture | 725% | 443% | 375% | 320% | 175% | 113% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 12 | 26 | 38 | 71 | 147 | 325 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PBM | |
|---|---|---|---|---|
| PBM | -93.7% | 534.3% | 0.56 | - |
| Sector ETF (XLV) | 0.3% | 17.6% | -0.13 | 8.8% |
| Equity (SPY) | 14.5% | 18.9% | 0.59 | 9.2% |
| Gold (GLD) | 50.2% | 27.7% | 1.46 | -13.6% |
| Commodities (DBC) | 17.8% | 17.6% | 0.85 | -19.1% |
| Real Estate (VNQ) | 0.4% | 16.4% | -0.15 | -0.6% |
| Bitcoin (BTCUSD) | -23.7% | 44.2% | -0.49 | -8.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PBM | |
|---|---|---|---|---|
| PBM | -81.4% | 386.6% | -0.12 | - |
| Sector ETF (XLV) | 6.0% | 14.5% | 0.23 | 6.8% |
| Equity (SPY) | 11.8% | 17.0% | 0.54 | 8.0% |
| Gold (GLD) | 20.7% | 17.7% | 0.96 | -9.8% |
| Commodities (DBC) | 11.6% | 18.9% | 0.50 | -12.9% |
| Real Estate (VNQ) | 3.0% | 18.8% | 0.07 | 1.4% |
| Bitcoin (BTCUSD) | 4.0% | 56.6% | 0.29 | -4.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PBM | |
|---|---|---|---|---|
| PBM | -56.9% | 386.6% | -0.12 | - |
| Sector ETF (XLV) | 9.7% | 16.5% | 0.48 | 6.8% |
| Equity (SPY) | 14.0% | 17.9% | 0.67 | 8.0% |
| Gold (GLD) | 13.3% | 15.8% | 0.70 | -9.8% |
| Commodities (DBC) | 8.2% | 17.6% | 0.39 | -12.9% |
| Real Estate (VNQ) | 4.7% | 20.7% | 0.19 | 1.4% |
| Bitcoin (BTCUSD) | 66.4% | 66.8% | 1.06 | -4.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.